Memorial Sloan Kettering researchers engineered a new uPAR-directed CAR T-cell therapy intended to expand cell therapy targeting beyond conventional antigens in solid tumors. The work centers on urokinase plasminogen activator receptor (uPAR), a protein implicated in tumor biology and microenvironment signaling. By focusing on uPAR, the program aims to address a long-standing limitation in solid-tumor CAR T approaches: achieving meaningful engagement and killing in heterogeneous tumor sites. The MSK update signals continued development activity around solid-tumor immunotherapies that can complement existing blood-cancer strengths.